Post-Approval Study Statements Now Expected In PMAs, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
Concerns about postmarket safety in the last few years have led to an FDA expectation that companies include post-approval study statements in their PMA submissions, CDRH Premarket Approval Section Director Thinh Nguyen says